Dymon Asia Capital (Singapore)’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
FP
TP
Dymon Asia Capital (Singapore)'s MRNA Position: Q3 2022 in Review
Dymon Asia Capital (Singapore) sold out of Moderna (MRNA) in Q3 2022, closing a stake of 12,131 shares — an estimated $1.73M sold.
Dymon Asia Capital (Singapore) first reported a position in MRNA in Q1 2021 and held it in 3 quarters. The position peaked at $1.73M in Q2 2022. 916 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.
- Dymon Asia Capital (Singapore) reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
- Dymon Asia Capital (Singapore) sold 12,131 Moderna shares in Q3 2022, an estimated $1.73M.
- Dymon Asia Capital (Singapore) first reported a position in Moderna in Q1 2021 and held it in 3 quarters.
- Dymon Asia Capital (Singapore)'s Moderna position peaked at $1.73M in Q2 2022.
- 916 funds tracked by Wall St. Rank held Moderna as of Q3 2022.
Based on Dymon Asia Capital (Singapore)'s 13F filing for Q3 2022, filed 14 Nov 2022.